Key Takeaways
- Strong FY23, Q4 margin dip is seasonal: Revenue grew 25% Y-o-Y with international profitability improving to ~11% EBITDA, but Q4 margins compressed 100–200 bps due to annual increments, year-end catch-up costs, and new entity consolidation.
- International business now the shock absorber: International EBITDA margin improved from 7.5%–8% at acquisition to ~11%, and its larger services/aftermarket mix means even a 6–9 month India slowdown would not derail overall numbers.
- Backlog and order intake remain strong: International visibility sits at 8–9 months, India at 6–7 months, and order intake continues strong into the new year, with systems orders expected to provide a near-term bump.
- Cost tailwinds are building: Metal prices have stabilized, natural gas costs fell steeply starting Q4, and lithium carbonate (key glass-lining input) saw a 50% cost reduction, setting up margin tailwinds if prices hold.
- What to watch next quarter: Whether the promised chemical and pharma capex cycle actually begins turning in late 2023, the pace of debt repayment from operating cash flow, and whether Mixel and JDS start contributing revenue and margin as planned.
Demand & Order Book
- Backlog visibility is solid: International business carries 8–9 months of visibility across most geographies, with some regions longer; India business holds 6–7 months. Order intake continues strong into the beginning of the new year.
- Systems business poised for a catch-up: The systems segment remains behind budget but carries a very strong opportunity pipeline; orders expected to finalize in coming months should give a nice bump to order intake.
- Chemical and pharma headwinds are temporary: Chemical order intake has slowed slightly in India but the opportunity pipeline is large; management believes chemicals will start ordering again. Pharma customers are planning large capex investments, with the ordering cycle expected to turn mid-2024 to 2025.
- European pharma demand is structurally supported: Shortages of basic medicals, especially for children, are motivating European governments to incentivize local pharmaceutical investment, a trend management expects to sustain for years.
- Large orders are landing: A large order from Cargill (U.S.) for heavy engineering equipment to be made in India was received in Q1 FY24. An acid recovery project (~$10 million) was won in Korea for a lithium application.
Thomas Kehl: "...we are experiencing, not only in Germany but in other countries in Europe, still a shortage of basic medicals, especially treating children. That's why the government to motivate and incentivize the pharmaceutical industries to invest locally in Germany and in other European countries and that will go on for quite a while."
International Business & Acquisitions
- International margin trajectory is up: International EBITDA margin improved to close to 11% from 7.5%–8% at acquisition. On a like-to-like basis excluding the three new entities, international margin is higher by ~0.5%. Management expects at least 100 bps further improvement.
- Three acquisitions are now consolidated: Hydro Air Research (Italy, started August), JDS Manufacturing (U.S., end of November, not yet producing), and Mixel Group (France and China, February, two months of revenue) are fully accounted for. JDS is a small glass-lining spare parts and reglass facility near Houston, currently in start-up phase.
- Mixel doubles down on mixing: The Mixel acquisition fits a global strategy to grow the mixing business to be as large as glass-lined. Backlog remains strong and the business is expected to at least double over the next 3–5 years, with plans to launch a unified global mixing brand.
- Hydro Air target: Management expects Hydro Air to at least double in the next three years.
- International business cushions India risk: Because international carries a larger share of services and aftermarket revenue, management is confident that even a 6–9 month India slowdown would not prevent hitting overall numbers.
Tarak Patel: "So, let's say, for example, if India were to slow down for the next 6-9 months, I'm still confident that the numbers will be met because the international business, with such a larger part of it coming from services and aftermarket, we will still continue to make those numbers."
Margins & Costs
- Q4 margin dip is seasonal, not structural: Q4 margins are historically lower by 100–200 bps due to the annual increment cycle starting January 1, year-end catch-up facilities expenses, and one-off payments. Three new entities distorted the quarterly comparison further. Full-year numbers are the right reflection for consistent expectations.
- Cost tailwinds are material: Metal prices have stabilized in India. Energy costs, mainly natural gas, saw a steep reduction starting Q4. Lithium carbonate, a key raw material for glass-lining, saw a 50% cost reduction. If these levels hold, a positive profitability impact is expected.
- Inventory accounting amplified last year's swings: The company uses moving average unit cost (MAUC), so every new purchase re-rates existing inventory. Last year, price benefits in H1 reversed in H2, causing margin improvement in H1 and impact in H2.
- Heavy engineering margin reset: The heavy engineering business was roughly breakeven this year due to higher input costs and large orders that were not margin-accretive. The backlog for next year is more margin-accretive and the booking strategy is now more careful.
- India margins under pressure: India margins are stable at 15% but face pressure from higher input costs and a slight slowdown in chemical and pharmaceutical investments.
Growth Engines: Mixing, Heavy Engineering & New Technologies
- Mixing business has scaled rapidly: Revenue grew from ₹25–30 cr to approximately ₹150 cr, driven by large fermentation reactor orders from three main customers in India manufacturing benzene. The backlog for next year remains strong.
- Non-glass-line technologies are growing fast: Wiped film evaporators and Equilloy (a technology product) both performed well, with very high double-digit growth rates across the non-glass-line portfolio.
- Heavy engineering poised for margin recovery: Growth will continue and margin improvement will be significantly better than the previous year, supported by a more margin-accretive backlog and more disciplined order booking.
- Manufacturing milestones: The company manufactured India's biggest glass-lined vessel (80,000 liters) with a backlog of more than 5–6 of these large sizes. The Chinese facility manufactured what is probably the world's biggest glass-lined vessel (about 140,000 liters).
- China is the real glass-line growth market: Market share in China is only ~10%, far below India (>50%), Europe (~40%), and the U.S. (30–35%). The China factory, started ~1.5 years ago, is fully operational with very strong momentum and can double or triple in the next period.
Balance Sheet, Cash Flow & Capital Allocation
- Working capital distorted by acquisitions: Negative INR 248 crores in working capital was driven by an increase in unbilled revenues due to global POC alignment, plus new entities' working capital added for the full year as a closing balance-sheet item while profit accumulated for only 2–3 months.
- Standalone India working capital improving: Improvement was seen in H2 and the company expects to continue improving working capital for an additional 3–4 days in upcoming years.
- Debt repayment is the near-term priority: No significant major acquisition is planned for the foreseeable future; focus is on reducing and repaying debt. Management expects to generate enough cash in the next 2–3 years to pay off gross debt (~₹800 cr) if no further acquisitions occur.
- U.S. pension plan cleaned up: Assets and liabilities of the U.S. funded pension plan have been knocked off.
- Promoter stake goal is 30%, not 50%+: The promoter's stated goal is to move closer to the 30% mark, with crossing 25% first as the most important threshold (hostile takeover protection, more promoter rights, ability to buy up to 5% per year from market without triggering an open offer). A 1% DBAG stake acquisition is awaiting FDI France clearance. No timeline can be given.
Manish Poddar: "We feel, in the next 2 to 3 years, we should generate enough cash. If we don't do any further acquisitions and all that, we should be able to pay off our debt in the next 3 years."
Capacity & Capex
- Existing capex can support more than FY25 targets: Management believes the existing capex infrastructure can support turnover closer to ₹4,000–4,000-plus crores, well above the FY25 guidance of ₹3,700 crores. No significant new capacity or headcount additions are planned; throughput will increase by moving production and engineering/documentation/calculations to India.
- Vatva and Hyderabad ramped: Both factories are fully up and running and accounted for more than INR 300 crores of revenue, up from zero not long ago. An operational excellence program was completed in Vatva and a new one has started in Hyderabad.
Manish Poddar: "...we generally believe that we can probably do closer to INR 4,000, INR 4,000-plus crores of the turnover out of the existing capex infrastructure that we have."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Growth rate to continue in the same region of about 15% | Ongoing |
| FY25 revenue | On track to surpass INR 3,700 crores | FY25 |
| FY25 EBITDA | INR 630 crores is something "we will definitely do" | FY25 |
| FY25 ROCE | 25% | FY25 |
| International margin improvement | At least 100 bps improvement from current ~11%–12% | Ongoing |
| Effective tax rate | Around 26%–27% on a go-forward basis | Ongoing |
| Chemical & pharma capex cycle | Ordering cycle expected to turn | Mid-2024 to 2025 |
| Hydro Air growth | Company to at least double | Next 3 years |
| Mixel growth | Business to at least double | Next 3–5 years |
| Debt repayment | Generate enough cash to pay off gross debt (~₹800 cr), absent further acquisitions | Next 2–3 years |
| Promoter stake | Cross 25% (awaiting FDI France clearance for 1% DBAG stake) | Undated |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹866 cr, +24% YoY |
| EBITDA | ₹96 cr, +34% YoY |
| EBITDA margin | 13.6% (FY23), +1.5 ppt YoY |
| PAT | ₹235 cr (FY23), 7.4% PAT margin |
| EPS | ~₹43 (FY23) |
| Order intake | ₹3,392 cr (FY23) |
| Order backlog | ₹2,162 cr as of Apr 1, 2023, evenly split between international and India |
| International business EBITDA margin | 8.9%, down from 12.7% QoQ (per an analyst's math); would be 0.5 ppt higher excluding new acquisitions |
| India business EBITDA margin | 15% (FY23), stable with some pressure from input costs and slower pharma/chem investment |
| International business revenue growth | 21% (FY23) |
| India business revenue growth | 32% (FY23) |
| FY25 revenue target | ₹3,700 cr, on track; existing capex can support closer to ₹4,000+ cr (per an analyst's math) |
| FY25 EBITDA target | ₹630 cr, on track |
| FY25 ROCE target | 25% |
| Consolidated net debt-to-EBITDA | 1x |
| Net debt-to-equity | 0.5x |
| Weighted average cost of capital | 7.7% global, 8.3% India |
| Mixing business revenue (India) | ~₹150 cr (FY23), up from ₹25–30 cr a few years ago |
| Heavy engineering | Breakeven (FY23); ₹100 cr of orders from one vendor were not margin-accretive |
| Market share (glass-lined) | >50% India, ~40% Europe, 30–35% U.S., ~10% China |
| Pension liabilities | ₹280 cr, down from ~₹373 cr at start of FY23 due to interest rate increases |
| Gross debt | ~₹800 cr, with ~₹300 cr cash; repayment schedule through FY28 |
| DBAG / Pfaudler Inc. stake | 14%; 1% acquisition awaiting FDI France clearance, which would take family stake above 25% |